Filing identity and reporting period
Important identity mismatch: The supplied filing is Nuvilex, Inc.’s Form 10-Q, not a filing identified in its text as Pharmacyte Biotech, Inc. It covers the three months ended July 31, 2012, Nuvilex’s fiscal first quarter. The financial statements are unaudited.
Business context
Nuvilex reported small product sales, principally associated with Cinnergen, while describing a broader biotechnology strategy that included pursuing a pancreatic cancer treatment. The company said it was directing resources toward acquiring and funding Austrianova Singapore Pte. Ltd. (ASPL).
Financial performance and liquidity
| Metric | Three months ended July 31, 2012 | Prior-year comparable period or balance-sheet comparison |
|---|---|---|
| Revenue | $6,626 | $19,762; down 66% |
| Gross profit / gross margin | $6,626 / 100% (no cost of revenue reported) | $4,087 / approximately 21% ($15,675 cost of revenue) |
| Operating expenses | $545,412 | $656,687 |
| Operating loss | $538,786 | $652,600 |
| Net loss | $510,517 | $686,020 |
| Operating cash flow | $(85,388) | $(119,627) |
| Investing cash flow | $(195,750), including acquisition-related payments | $(320,000) |
| Financing cash flow | $289,757 | $465,500 |
| Cash | $24,342 at July 31 | $15,723 at April 30, 2012 |
| Current assets / current liabilities | $1,205,658 / $4,027,026 | $1,058,730 / $3,787,358 at April 30, 2012 |
| Working capital | $(2,821,368) | Not stated as a comparable figure |
| Total liabilities / stockholders’ deficit | $4,027,026 / $(2,372,590) | $3,787,358 / $(2,279,850) at April 30, 2012 |
Interest expense was $46,063. Other income included a $71,742 gain on debt forgiveness and $2,590 of other income. The reported basic loss per share was $(0.00), rounded, on weighted-average shares of 419,566,403.
Material changes and financing
- Revenue fell by $13,136 year over year. Management attributed limited marketing investment to prioritizing ASPL and the anticipated acquisition.
- Operating expenses declined $111,275, mainly because compensation expense fell by $124,383 as fewer shares were issued to officers. General and administrative expense rose $63,967, largely due to investor-relations costs.
- Net loss improved by $175,503, reflecting lower operating expenses and the change from prior-year other expense to current-period other income.
- Cash from operations remained negative; financing included $250,000 of note proceeds and $39,757 of related-party borrowings. The company also issued shares for services, officer compensation, and debt settlement. Shares outstanding were 423,420,851 at July 31 and 423,950,851 as of September 10, 2012.
- At July 31, loans payable were $730,000 on the balance sheet. The debt note describes $310,000 of individual notes at 10% due within one year, a separate $20,000 note plus accrued interest at 8% that was past due, and a $400,000 licensing-fee obligation under a terminated agreement that was being negotiated for settlement. The filing also reports $2,225,313 of current settlement-obligation liabilities.
Outlook, risks, and unusual items
- Going concern: Management stated that revenue was insufficient to cover operating costs, cited the $40.36 million accumulated deficit and negative working capital, and acknowledged substantial doubt about the company’s ability to continue as a going concern. Continued operations depend on external funding; the filing provides no firm financing assurance.
- ASPL transaction: Nuvilex reported purchasing all ASPL shares on June 21, 2012 in exchange for 100 million restricted common shares. The shares were held in escrow and excluded from the financial statements pending satisfaction of the agreement’s funding requirements. Nuvilex committed to fund $2.5 million, targeted by December 31, 2012, and to continue $60,000 monthly operating support. Failure to meet the requirements could unwind the transaction.
- Cornerstone Bank settlement: A May 2012 agreement addressed debt reported at approximately $2.0 million. It provided for a two-year stay of execution, transfer of the property to the bank for sale proceeds to reduce the debt, and 14,605,614 shares as collateral. The balance sheet continued to report a $1,028,778 settlement asset and $2,225,313 settlement liability while the obligation remained unresolved.
- Controls: Management concluded internal control over financial reporting was ineffective at July 31, citing incompletely developed accounting policies and procedures and the absence of an audit committee financial expert. Management said it was beginning work to implement a COSO-based framework.
- Risks highlighted include dependence on future capital, early-stage and unpredictable revenues, competition, product and regulatory risks, dependence on key personnel, and stock-price volatility. The filing gives no quantitative revenue or earnings guidance.
Investor verification points
- Confirm the filing belongs to the intended issuer: the supplied document names Nuvilex, Inc., not Pharmacyte Biotech, Inc.
- Verify the status and accounting treatment of the ASPL acquisition, escrowed 100 million shares, required $2.5 million funding, and monthly support payments.
- Assess near-term liquidity and the availability and terms of additional financing, given cash of $24,342, negative working capital, and the going-concern warning.
- Confirm the amount, maturity, settlement status, and potential dilution associated with debt, the Cornerstone obligation, related-party advances, and share issuances.
- Review progress addressing the disclosed material weakness in internal controls and any later changes in financial reporting controls.